Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Hims & Hers stock has dropped over 60% from its peak due to concerns about its GLP-1 business. Read why I think HIMS stock is ...

Zacks Equity Research shares Hims & Hers Health HIMS as the Bull of the Day and AST SpaceMobile ASTS as the Bear of the D ...

Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss ...

Eli Lilly (LLY) stock surges after releasing promising test results from the company's GLP-1 pill, which would serve as an alternative to injectable weight-loss drugs. Novo Nordisk (NVO) and Hims & ...

Hims & Hers' Chief Operating Officer Melissa Baird will transition into an advisory role with the telehealth company in the coming months.

We recently published a list of 10 Best Telehealth Stocks to Buy Now. In this article, we are going to take a look at where ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Overall, Novo is expecting slower growth in 2025. The company is guiding for sales to rise between 16% and 24%, down from 26% ...

This has been the primary concern for investors with HIMS as the GLP-1 weight loss space is filled with volatility due to competition and falling margins. Primary Care: Expanding into chronic ...